Orphazyme A/S (NASDAQ:ORPH) was downgraded by equities research analysts at Guggenheim from a “neutral” rating to a “sell” rating in a report issued on Monday, Analyst Price Targets reports.
Several other equities research analysts have also commented on ORPH. Zacks Investment Research lowered shares of Orphazyme A/S from a “hold” rating to a “sell” rating in a research report on Thursday, June 3rd. Cowen lowered shares of Orphazyme A/S from an “outperform” rating to a “market perform” rating in a report on Friday, June 18th. Finally, Bank of America lowered shares of Orphazyme A/S from a “neutral” rating to an “underperform” rating and reduced their target price for the stock from $13.00 to $5.00 in a report on Tuesday, March 30th.
NASDAQ ORPH opened at $5.97 on Monday. Orphazyme A/S has a 52 week low of $4.75 and a 52 week high of $77.77. The stock has a market cap of $208.66 million and a price-to-earnings ratio of -1.75. The company has a quick ratio of 4.70, a current ratio of 4.70 and a debt-to-equity ratio of 0.05. The company’s 50-day simple moving average is $7.91.
About Orphazyme A/S
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases.
Recommended Story: How Does the Quiet Period Work?
Receive News & Ratings for Orphazyme A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orphazyme A/S and related companies with MarketBeat.com's FREE daily email newsletter.